The company's financial position is characterized by a shrinking asset base, which contracted from $114.1 million in 2025Q4 to $92.0 million by 2026Q3.
| Total Current Assets | 34.86M | 56.71M | 72.5M | 82.94M | 108.35M | 14.76M | 9.83M | 13.26M | 44.51M | 12.17M | 2.61M |
| Cash & Short-Term Investments | - | - | - | - | - | - | - | - | - | - | - |
| Cash Only | 30.5M | 52.77M | 2.67M | 21.5M | 26.54M | 7.85M | 6.21M | 12.02M | 15.8M | 11.76M | 2.34M |
| Short-Term Investments | 0 | 0 | 63.27M | 58.01M | 36.7M | 0 | 0 | 0 | 24.7M | 0 | 0 |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - | - |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 276K | 281K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 399.9 | 243.04 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.79M | 786K | 430K | 914K | 44.81M | 5M | 3.23M | 0 | 0 | 0 | 17K |
| Total Non-Current Assets | 57.13M | 57.39M | 24.33M | 15.89M | 9.97M | 139.29M | 126.52M | 128.88M | 72.41M | 74.04M | 61.7M |
| Property, Plant & Equipment | 1.52M | 1.6M | 2.12M | 1.7M | 1.77M | 1.84M | 44.43M | 48.73M | 50.11M | 51.16M | 50.97M |
| Fixed Asset Turnover | 0.63x | 0.57x | 0.30x | 0.16x | 0.23x | 0.44x | 0.11x | 0.10x | 0.09x | 0.11x | 0.11x |
| Goodwill | 19.94M | 19.94M | 3.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 896K | 32.57M | 1.85M | 1.57M | 1.57M | 1.57M | 1.57M | 1.57M | 1.65M | 0 | 0 |
| Long-Term Investments | 0 | - | - | - | - | - | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - | - | - | - | - | - | - |
| Total Assets | 91.99M | 114.11M | 96.83M | 98.83M | 118.32M | 154.06M | 136.35M | 142.14M | 116.92M | 86.2M | 64.31M |
| Asset Turnover | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.04x | 0.03x | 0.04x | 0.07x | 0.09x |
| Asset Growth % | 42.51% | 17.84% | -2.02% | -16.47% | -23.2% | 12.99% | -4.08% | 21.57% | 35.63% | 34.05% | - |
| Total Current Liabilities | 11.02M | 11.6M | 7.51M | 2.15M | 21.03M | 17.3M | 5.73M | 1.43M | 891K | 363K | 302K |
| Accounts Payable | 7.04M | 6.89M | 2.56M | 333K | 564K | 1.16M | 921K | 795K | 367K | 115K | 64K |
| Days Payables Outstanding | 10.51K | 5.96K | 6.06K | - | - | 6.05K | - | - | - | - | - |
| Short-Term Debt | - | - | - | - | - | - | - | - | - | - | - |
| Deferred Revenue (Current) | 0 | - | - | - | - | - | - | - | - | - | - |
| Other Current Liabilities | 3.37M | 3.28M | 113K | 1.05M | 3.59M | 252K | 4.81M | 27K | 24K | 35K | -278K |
| Current Ratio | 3.16x | 4.89x | 9.65x | 38.67x | 5.15x | 0.85x | 1.72x | 9.29x | 49.96x | 33.52x | 8.65x |
| Quick Ratio | 3.14x | 4.86x | 9.65x | 38.67x | 5.15x | 0.85x | 1.72x | 9.29x | 49.96x | 33.52x | 8.65x |
| Cash Conversion Cycle | -10.11K | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 167K | 4.14M | 3.06M | 55K | 88K | 48K | 92K | 15.95M | 464K | 23.76M | 15.19M |
| Long-Term Debt | 2K | 78K | 73K | 0 | 0 | 0 | 0 | 14.95M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | - | - | - | - | - | - | - | - | - | - |
| Deferred Tax Liabilities | 0 | - | - | - | - | - | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | 11.19M | 15.74M | 10.57M | 2.2M | 21.11M | 17.35M | 5.82M | 17.38M | 1.35M | 24.13M | 15.5M |
| Total Debt | 610K | 692K | 2.39M | 0 | 15M | 14.53M | 0 | 14.95M | 0 | 0 | 0 |
| Net Debt | -29.89M | -52.08M | -288K | -21.5M | -11.54M | 6.67M | -6.21M | 2.92M | -15.8M | -11.76M | -2.34M |
| Debt / Equity | 0.01x | 0.01x | 0.03x | - | 0.15x | 0.11x | - | 0.12x | - | - | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.83x | - | - | - | - | - | - | - | - | -6.22x | -0.83x |
| Interest Coverage | - | -49.45x | -270.21x | - | -23327.67x | -1951.17x | -81.95x | -7.48x | - | - | 59.60x |
| Total Equity | 80.8M | 98.37M | 86.26M | 96.63M | 97.21M | 136.7M | 130.53M | 124.76M | 115.56M | 62.08M | 48.81M |
| Equity Growth % | 39.63% | 14.04% | -10.73% | -0.59% | -28.89% | 4.73% | 4.62% | 7.96% | 86.16% | 27.18% | - |
| Book Value per Share | 1.58 | 3.34 | 3.63 | 4.15 | 4.92 | 8.27 | 8.28 | 9.40 | 9.26 | 4.95 | 3.89 |
| Total Shareholders' Equity | 75.39M | 94.39M | 82.19M | 100.29M | 100.52M | 122.29M | 116.8M | 110.98M | 106.7M | 52.74M | 48.81M |
| Common Stock | 521K | 516K | 246K | 244K | 245K | 177K | 157K | 139K | 126K | 50.43M | 48.62M |
| Retained Earnings | -252.72M | -232.26M | -201.74M | -167.33M | -165.46M | -40.8M | -16.25M | -5.84M | -1.11M | 0 | 0 |
| Treasury Stock | -168K | -168K | -168K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.52M | 4.14M | 111K | 3.37M | 3.7M | 3.77M | 3.76M | 3.78M | 4.04M | 2.32M | 189K |
| Minority Interest | 5.42M | 3.98M | 4.07M | -3.66M | -3.31M | 14.42M | 13.73M | 13.78M | 8.87M | 9.34M | 0 |
Clinical Trial Burn Rate
According to recent quarterly filings, Rafael Holdings' total assets have contracted from $114.1 million in 2025Q4 to $92.0 million by 2026Q3, reflecting a consistent erosion of the balance sheet as the company funds its clinical-stage pharmaceutical operations through its existing cash reserves.
The steady decline in total assets suggests that the company is consuming its capital base to sustain operations rather than generating internal growth. Investors should monitor whether this trajectory leads to a critical liquidity threshold, as the current rate of asset depletion appears unsustainable without a strategic pivot or external capital infusion.
As reported in financial statements, the company's cash position has declined from a peak of $52.8 million in 2025Q4 to $30.5 million in 2026Q3, indicating a rapid consumption of liquidity that warrants close attention from stakeholders evaluating the firm's long-term viability.
While the current ratio of 3.16 remains technically healthy, the absolute decline in cash reserves highlights the company's dependence on its existing balance sheet to cover ongoing R&D and administrative costs. This trend suggests that the company's liquidity buffer is narrowing, potentially limiting management's flexibility to pursue future clinical or real estate opportunities.
Based on RFL's reported figures, the retained earnings deficit has deepened significantly to -$252.7 million as of 2026Q3, underscoring the persistent value destruction inherent in the company's current business model of funding high-risk oncology research through limited real estate income.
The widening deficit in retained earnings reflects the cumulative impact of years of operating losses, which continue to weigh heavily on the equity base. This trend suggests that the company's capital structure is increasingly reliant on its initial equity cushion, as the core business operations have yet to demonstrate a path toward profitability.
Financial data from recent periods reveals significant fluctuations in goodwill, which spiked to $28.3 million in 2025Q3 before settling at $19.9 million, suggesting that the company's balance sheet is subject to non-operational accounting adjustments that may obscure the underlying value of its core assets.
The volatility in intangible assets warrants further investigation, as it may indicate periodic impairments or revaluations of the company's pharmaceutical interests. Investors should be cautious, as these accounting shifts can mask the true economic reality of the company's asset base and its ability to generate future returns.
Quick answers to the most common questions about buying RFL stock.
As of 2025, Rafael Holdings, Inc. (RFL) had total assets of $114.1M including $56.7M in current assets.
Rafael Holdings, Inc. (RFL) carries total debt of $0.7M. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Rafael Holdings, Inc. (RFL) has total shareholders' equity (book value) of $94.4M ($3.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Rafael Holdings, Inc. (RFL) reported a current ratio of 4.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.